Entering text into the input field will update the search result below

Biogen, Eisai begin filing application data for Alzheimer's drug lecanemab in Japan

Mar. 04, 2022 6:18 AM ETEisai Co., Ltd. (ESALY), BIIBBy: Ravikash, SA News Editor

Naeblys/iStock via Getty Images

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY) began submission of application data in Japan aimed at getting an early approval of their Alzheimer's disease (AD) therapy lecanemab.

Eisai began a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.